Artemisinin Partial Resistance Mutations in Zanzibar and Tanzania Suggest Regional Spread and African Origins, 2023

Sean V. Connelly[1#], Julia G. Muller[2#], Mohamed Ali[3], Billy E. Ngasala[4,5], Wahida Hassan[3], Bakari Mohamed[3], Kyaw L. Thwai[2], Jacob M. Sadler[2], Jacob Marglous[6], Abebe A. Fola[6], Abdallah Zacharia[4], Shija J. Shija[3], Safia Mohammed[3], Msolo C. Dominick[4], Hamza Said[4], Editruda E. Peter[4], Melic Odas[4], Isaack J. Rutha[4], Mwanaidi Nwange[4], Karamoko Naire[6], Shazia Ruybal-Pesántez[7,8], Robert Verity[7], Rebecca Crudale[6], Varun Goel[9], Barbara B. Choloi[2], Anders Björkman[10], Jeffrey A. Bailey[6*], Jessica T. Lin[2,11,12*], Jonathan J. Juliano[2,12,13, 14*]

1: MD-PhD Program, University of North Carolina, Chapel Hill, NC 27599, USA
2: Division of Infectious Diseases, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
3: Zanzibar Malaria Elimination Program (ZAMEP), Zanzibar, Tanzania
4: Department of Parasitology and Medical Entomology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
5: Department of Women's and Children's Health, International Maternal and Child Health (IMCH), Uppsala University, Uppsala, Sweden
6: Department of Pathology and Laboratory Medicine, Brown University, Providence, RI 02912, USA
7: MRC Centre for Global Infectious Disease Analysis, Imperial College, London, UK
8: Instituto de Microbiología, Universidad San Francisco de Quito, Ecuador
9: Department of Geography, University of South Carolina, Columbia, SC 29208, USA
10: Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
11: Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA
12: Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
13: Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA
14: Curriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill, NC 27599, USA

Brief Title: ART-R in Zanzibar

Key words: malaria, Plasmodium, falciparum, antimalarial resistance, artemisinin, Zanzibar

#: Co-first authors
*: Co-senior authors

Corresponding Author:
Jonathan Juliano, MD
110 Mason Farm Rd.
CB#7036
University of North Carolina
Chapel Hill, NC 27599
jjuliano@med.unc.edu
919-843-5065

ABSTRACT

Artemisinin partial resistance (ART-R) in East Africa, driven by *Plasmodium falciparum* K13 mutations, threatens malaria control. Zanzibar, adjacent to Tanzania, is vulnerable to ART-R spread but lacks recent molecular surveillance. We sequenced antimalarial resistance polymorphisms from samples in Zanzibar and mainland Tanzania collected in 2022-2023. K13 mutations (P441**L**, A675**V**) were found in 2/1440 Zanzibar participants and 6/3760 (R561**H**, P441**L**) in mainland Tanzania. Whole genome sequencing supports the mutations African origins and regional spread. Frequent parasite importation to Zanzibar and partner drug mutation frequencies support current ACT policy but underscore the need for continued surveillance.

MANUSCRIPT

East Africa is facing a potential public health crisis with the emergence of artemisinin partial resistance (ART-R) in the region [1]. ART-R can be mediated by mutations in *Plasmodium falciparum* kelch 13 (K13), which have been correlated with *in vivo* phenotypes of ART-R, prolonged parasite clearance and longer clearance half lives. K13 polymorphisms are now found at a moderate prevalence in certain parts of Rwanda, Ethiopia, Tanzania and Uganda, with isolates containing the mutations found sporadically across the entire East Africa region [1]. A concern is that ART-R will set the stage for partner drug resistance to emerge in Africa, as more parasites will be exposed to partner drug monotherapy as a part of artemisinin combination therapies (ACTs) [1]. Mutations that confer partner drug resistance that already exist in Africa may also potentiate the spread of ART-R, as was seen with mefloquine in Asia [2].

Zanzibar is a semi-autonomous archipelago off the coast of Tanzania, with an independent malaria control program and Ministry of Health. Unlike mainland Tanzania, where some regions have moderate to high levels of transmission, Zanzibar has been a pre-elimination setting for almost a decade, with low levels of transmission and susceptibility to outbreaks [3]. Much of the malaria in Zanzibar is thought to be imported from the adjacent Tanzanian mainland [3]. Zanzibar is likely at increased risk for ART-R given emergence of the validated R561H mutation in Kagera region in northwestern Tanzania [4], the relatively low immunity from years of malaria control, and the presence of competent Anopheline vectors. Previous molecular surveillance in 2017 showed no K13 polymorphisms and low levels of mutations in genes associated with tolerance to partner drugs [5].

We leveraged molecular inversion probes (MIPs) sequencing targeting key antimalarial resistance mutations of 5,200 samples collected at 100 health facilities in Unguja, Zanzibar and from 29 health facilities in 24 districts from mainland Tanzania between May 2022 and December 2023 (**Figure 1**). The mainland health facilities were selected in regions most commonly reported as travel destinations by Zanzabaris with malaria that were investigated the previous year by the Zanzibar Malaria Elimination Program (ZAMEP). Zanzibari health facilities were selected using a stratified random sampling approach to draw evenly from urban and rural areas and sample roughly half of malaria cases across the main island of Unguja, with the goal of enrolling every malaria case presenting at the participating clinic. Health facility staff were trained by the research team to consent participants, collect dried blood spots (DBS) on Whatman 3 filter paper, and conduct a brief survey of clinical, behavioral, demographic and travel related questions. Consents, case report forms, and DBS were packaged by the health facility staff and collected by the research team during site visits and audits. Packets were returned to the Muhimbili University of Health and Allied Sciences (MUHAS) lab in Bagamoyo, Tanzania where consents were confirmed, surveys were scanned into an electronic database using ABBYY Flexcapture software, and DBS punched into 96 deep well plates (3 punches per sample). All data scanned were manually checked by research staff. The number of samples sequenced from each health facility is shown in **Table S1** and the seasonality of collections of sequenced samples in Zanzibar and the mainland are shown in **Figure S1**. Participants exhibited some demographic differences; namely, the majority of malaria cases in Zanzibar

were in males (66.9% in Zanzibar vs. 46.6% in mainland), and malaria cases in mainland Tanzania tended to be younger aged children (**Table S2**). Mainland Tanzania malaria cases also exhibited higher median parasite density compared to those from Zanzibar (6,650 p/µL in mainland vs. 3,790 p/µL in Zanzibar). Among the Zanzibari participants sequenced, 564/1440 (39.2%) reported travel to the mainland in the preceding 28 days.

Samples were shipped to the University of North Carolina where DNA was extracted from the DBS using a Chelex extraction method. Parasitemias were estimated using an ultrasensitive real-time PCR targeting the *varats* gene using mocked blood spots at various concentrations as controls [6]. The mock blood spots were generated by mixing culture grown 3D7 (MRA-102, BEI, Manasas, VA) with whole blood at specific parasitemias, which was spotted and dried on filter paper. Extracted DNA was then sent to Brown University to undergo MIP capture and sequencing of known antimalarial resistance polymorphisms as previously described [7]. Resulting data were analyzed using MIPtools software with freebayes variant calling (https://github.com/bailey-lab/MIPTools) [7]. Controls for each MIP capture and sequencing included DNA from 3D7 and 7G8 (MRA-102G and 152G, BEI) as well as no template and no probe controls. Variant calling was conducted as previously described [7]. Samples were filtered based on UMI (unique molecular identifier) coverage of greater than or equal to 5 UMIs per locus. Mutation prevalence was determined by dividing the sum of the mixed genotype and pure resistant individuals by the total amount of pure resistant, mixed and reference individuals. Prevalence was determined per region (mainland Tanzanian samples, Zanzibari travelers or Zanzibari non-travelers). A 95% confidence interval was calculated with the Pearson-Klopper exact method.

A total of 1,440 Zanzibari and 3,760 mainland samples were successfully genotyped. K13 mutations detected are summarized in **Figure 1** and **Table S3**. Among the Zanzibari isolates, we identified 2 samples with WHO validated or candidate ART-R K13 polymorphisms. One sample collected in Kati district (central Unguja) from a 15 year-old female who did not identify as a permanent Zanzibari resident and had recently traveled to Kigoma district (western Tanzania, bordering the Democratic Republic of the Congo) contained the P441**L** mutation. The second was collected in Kusini (southeast Unguja) from a 21 year-old student who had not traveled in the last 28 days and contained the A675**V** mutation. Interestingly, R561**H,** which has been detected throughout the Great Lakes region including in Tanzania, was not observed in Zanzibar. On the mainland, 3 isolates contained the P441**L** mutation (2 from Gairo in the central Morogoro region, 1 from the Nzega district of Tabora in northwest Tanzania) and 3 contained the R561**H** mutation, all from the Kilosa district of Morogoro. The prevalence of molecular markers for all other antimalarials was similar between Zanzibar and the mainland (**Figure S2** and **Table S4**), including commonly identified wild type *P. falciparum* multi drug resistance protein 1 (MDR1) **N**86Y allele, associated with increased tolerance to lumefantrine, and uncommon *P. falciparum* chloroquine resistance transporter (CRT) K76**T** and MDR1 N86**Y** mutant alleles associated with tolerance to amodiaquine (AQ). However, there were some subtle differences between our previous report leveraging samples from 2016-2018 and current estimated prevalences from samples collected 2022-2023 [10]. For example, dihydropteroate synthase (DHPS) A581**G** mutation increased in prevalence in Zanzibar from 0.04 (8/181, 95% CI: 0.02–0.09) to 0.12 (142/1181, 95% CI: 0.10-0.14) ($p = 0.004$).

ART-R mutations are now being seen in Zanzibar and raise concern over the spread of artemisinin partial resistance to this receptive low transmission region. Similar to previous work, ART-R polymorphisms remain spotty on the mainland, but are detectable [4]. This study did not sample in the Kagera region where K13 mutations have been commonly found [4,8]. The A675**V** mutation was originally described in Uganda, but has spread regionally and has been reported in Tanzania previously [4]. The P441**L** mutation has also already been described in multiple locations in East Africa [4,9], and now Southern Africa. However, this is the first reported detection of this mutation in Tanzania.

We assessed the extended haplotypes around K13 from all mutant isolates detected in the study by conducting whole genome sequencing, comparing to publicly available African and Asian genomes containing mutant R561**H**, A675**V** and P441**L** (**Table S5**). Methods are described in the **Supplementary Materials**. Of 8 mutant isolates from Zanzibar or the mainland, we generated high quality genomes for seven (3 R561**H**, 1 A675**V** and 3 P441**L)** isolates. The R561H isolates from the Morogoro region cluster with the previously described TZ2 haplotype identified in Kagera in 2021 (**Figure S3**).[4] The isolate with A675**V** clustered with wild type isolates from Africa (no mutant African A675**V** genomes were available) and not with A675**V** mutant isolates from Asia (**Figure S4**). Lastly, for P441**L**, the 2 isolates from Gairo, Tanzania and single isolate from Zanzibar cluster together and are more closely related to African isolates, rather than Asian P441**L** mutant isolates (no mutant African P441**L** genomes were available) (**Figure 2**). These preliminary findings suggest regional transmission of R561**H** and P441**L** clones is occurring within Tanzania, including to Zanzibar. These are the first A675**V** and P441**L** isolates sequenced from Africa and data supports novel African haplotypes rather than haplotypes from Asia. One of the two cases of K13 mutations in Zanzibar did have recent travel that suggests importation from Kigoma, but additional sequencing of isolates outside of Tanzania to assess extended haplotypes around the K13 locus is needed to better understand if these parasites are related to parasites carrying the same mutation in other regions of East Africa.

Zanzibar continues to use artesunate-amodiaquine (AS-AQ) as its first line antimalarial, while mainland Tanzania uses artemether-lumefantrine (AL). AQ and lumefantrine have differential selection on key antimalarial resistance polymorphisms, in particular MDR N86Y and CRT K76T, where lumefantrine selects for the wild type and AQ selects for the mutant [11]. The finding of a resistance pattern more similar to regions that use AL (such as the mainland, **Figure S2**) on Zanzibar strongly suggests that importation is a major driver shaping the parasite population, as the opposite signatures of selection on antimalarial resistance markers would be expected based on first-line therapy in Zanzibar.

Given the large numbers of clinics, the number of samples sequenced to date does not enable a refined understanding of differences on a local scale. However, additional sequencing of isolates is ongoing. We are also limited by the relatively few number of sites from the mainland where samples were collected. This could be overcome by accessing samples from other large studies, such as school-aged children surveys [12] or other major surveillance efforts. Currently, we cannot deduce the source of these K13 mutations. Eventually as more whole genomes become available from African isolates with different mutations, it will be possible to

use analysis of K13 flanking haplotype to determine if these are imported cases from other areas of Tanzania and Africa, or if they are independent origins arising locally [4].

The emergence of ART-R is concerning for the longevity of ACTs in Africa. To date, efficacy generally remains high despite the presence of K13 mutations [8,13]. However, if partner drug resistance emerges, the impact could be profound. To date, there is no evidence of high-level resistance to lumefantrine or amodiaquine, the two most common partner drugs used in Africa, but isolated reports of clinical failure and trends toward higher rates of reduced sensitivity to lumefantrine are concerning [14,15]. In Zanzibar, we identified two isolates with K13 mutations. It is possible that the use of AS-AQ in Zanzibar has helped to reduce onward transmission of K13 mutations introduced,given the favorable partner drug tolerance profile. For now, widespread routine molecular surveillance for polymorphisms associated with antimalarial resistance remains the best early warning sign for potential clinical problems with ACTs in the future.



Figure 1. Map of health facilities for the study and locations of isolates with K13 artemisinin partial resistance mutations. Panel A shows locations of health facilities in the mainland and Panel B shows health facilities in Unguja, Zanzibar. In total, 3,760 samples from 29 clinics in mainland Tanzania and 1,440 from 100 clinics in Zanzibar were genotyped.



Figure 2. Extended Haplotype Analysis of P441L K13 Mutant Isolates from Zanzibar and Tanzania. Extended haplotypes 50kb upstream and downstream of the P441L mutation (chr13:1725676) were compared between mainland Tanzania, Zanzibari, and publicly available Southeast Asian (SEA) genomes. Mutants from the mainland (red: TZ-22-) and Zanzibar (red: ZB-22-) cluster with wildtype parasites from mainland Tanzania (green: MSMT-) and appear distinct from mutant P441L samples from Asia (blue: PD-, Thailand; QC-/RCN-, Myanmar). The parasites from Zanzibar also appear distinct from wildtype SEA (purple: PD- Thailand) and Rwandan samples (green: ERR-). Taken together, this suggests transmission between mainland Tanzania and Zanzibar, and an African origin of these P441L mutants.

Acknowledgements: We thank the study participants who donated their time and the health facility staff who collected samples for the study. We thank the ZAMEP district malaria surveillance officers who were instrumental to the successful implementation of the study. The following reagent was obtained through BEI Resources, NIAID, NIH: *P. falciparum*, Strain 3D7, MRA-102, contributed by Daniel J. Carucci. The following reagent was obtained through BEI Resources, NIAID, NIH: Genomic DNA from *P.falciparum*, Strain 3D7, MRA-102G, contributed by Daniel J. Carucci. The following reagent was obtained through BEI Resources, NIAID, NIH: Genomic DNA from *P. falciparum*, Strain 7G8, MRA-152G, contributed by David Walliker.

Ethics Statement: The study was approved by the institutional review board (IRB) in Zanzibar (ZAHREC/01/EXT/July/2023/03), at MUHAS (MUHAS-REC-02-2024-1168), and at UNC (21-1966). Written informed consent, parental consent and/or assent were provided by all participants.

Data Availability: Sequencing data are available at (SRA number pending). Metadata are available upon request to the corresponding author. Custom scripts are available at https://github.com/sconnelly007/ZIM_ART_R.

Conflicts of Interest: Authors have no competing interests to declare. Generative AI was used in the drafting of this manuscript. The authors take responsibility for the contents.

Author contributions: Conception and design: JJJ, JTL, BEN, JAB, MA, WH, AB; Data acquisition, analysis and interpretation: SVC, JGM, MA, WH, BM, JMS, JM, AF, KN, AZ, MCD, RC, KLT, VG, BBC, EEP, MO, IJR, MN, SRP, BV, HS; Drafting manuscript: SVC, JGM, AF, JTL, JJJ, JAB; Revision and final approval: All authors; Accountability: SVC, JGM, JAB, BEN, JTL, JJJ

Funding: This project was funded by the National Institutes for Allergy and Infectious Diseases (R01AI155730 to JJJ, JTL and BEN; K24AI134990 to JJJ; F30AI183592 to SVC).

REFERENCES

1. Rosenthal PJ, Asua V, Bailey JA, et al. The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect Dis. **2024**; 24(9):e591–e600.

2. Björkman A, Gil P, Alifrangis M. Alarming Plasmodium falciparum resistance to artemisinin-based combination therapy in Africa: the critical role of the partner drug. Lancet Infect Dis. **2024**; 24(9):e540–e541.

3. Björkman A, Shakely D, Ali AS, et al. From high to low malaria transmission in Zanzibar—challenges and opportunities to achieve elimination. BMC Med. **2019**; 17(1):14.

4. Juliano JJ, Giesbrecht DJ, Simkin A, et al. Prevalence of mutations associated with artemisinin partial resistance and sulfadoxine-pyrimethamine resistance in 13 regions in Tanzania in 2021: a cross-sectional survey. Lancet Microbe. **2024**; :100920.

5. Msellem M, Morris U, Soe A, et al. Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar. Emerg Infect Dis. **2020**; 26(8):1767–1777.

6. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS Med. **2015**; 12(3):e1001788.

7. Verity R, Aydemir O, Brazeau NF, et al. The impact of antimalarial resistance on the genetic structure of Plasmodium falciparum in the DRC. Nat Commun. **2020**; 11(1):2107.

8. Ishengoma DS, Mandara CI, Bakari C, et al. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. Lancet Infect Dis [Internet]. **2024**; . Available from: http://dx.doi.org/10.1016/S1473-3099(24)00362-1

9. Wernsman Young N, Gashema P, Giesbrecht D, et al. High frequency of artemisinin partial resistance mutations in the Great Lakes region revealed through rapid pooled deep sequencing. J Infect Dis [Internet]. **2024**; . Available from: http://dx.doi.org/10.1093/infdis/jiae475

10. Connelly SV, Brazeau NF, Msellem M, et al. Strong isolation by distance and evidence of population microstructure reflect ongoing transmission in Zanzibar. Elife [Internet]. **2024**; 12. Available from: http://dx.doi.org/10.7554/eLife.90173

11. Yeka A, Kigozi R, Conrad MD, et al. Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial. J Infect Dis. **2016**; 213(7):1134–1142.

12. Sendor R, Mitchell CL, Chacky F, et al. Similar Prevalence of Plasmodium falciparum and Non-P. falciparum Malaria Infections among Schoolchildren, Tanzania. Emerg Infect Dis. **2023**; 29(6):1143–1153.

13. Uwimana A, Legrand E, Stokes BH, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. Nature Publishing Group; **2020**; 26(10):1602–1608.

14. Schalkwyk DA van, Pratt S, Nolder D, et al. Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine. Clin Infect Dis. Oxford Academic; **2023**; 78(2):445–452.

15. Tumwebaze PK, Conrad MD, Okitwi M, et al. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat Commun. Nature Publishing Group; **2022**; 13(1):1–12.